Impact of Phase II Trials with Progression-free Survival As End-points on Survival-based Phase III Studies in Patients with Anaplastic Gliomas

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2007 Jun 26

PMID 17587447

Citations 10

Authors

Victor A Levin

Sandra Ictech

Kenneth R Hess

Affiliations

Soon will be listed here.

Abstract

Background: To assess progression-free survival (PFS) as the appropriate end-point for phase II trials for anaplastic gliomas (AGs) and to determine the impact of PFS on survival-based phase III trials.

Methods: Combined data from 16 phase II studies (N = 529 patients) were analyzed to determine progression-free survival (PFS) at 6, 9, and 12 months and the impact of age, Karnofsky performance score (KPS), number of prior chemotherapies, and response to treatment on PFS.

Results: The specific chemotherapy used was the major effector of PFS at 6, 9, and 12 months. Age, KPS, treatment response rate, and number of prior chemotherapies did not affect PFS to the same extent. Hierarchical cluster analyses and linear least squares fitting of PFS9 v PFS12 demonstrated the existence of three therapeutic efficacy groups with PFS rates at 6, 9, and 12 months ranging from lowest (A) to highest (C). The PFS6 was 15% in group A and 41% in group C (p < .0001); the PFS12 was 9% in group A and 33% in group C (p < .0001). Further, 80% of patients at recurrence had a 23% likelihood that each chemotherapy would provide > 1 year of additional life.

Conclusion: Based on PFS rates at 6, 9, and 12 months for AG patients, a differential of 1.5 to 2 years is the norm and could invalidate overall survival as an end-point for phase III studies in patients with AG. PFS is a more reliable end-point because it reflects the true antitumor benefit of the chemotherapy.

Citing Articles

Clinical trial endpoints for patients with gliomas.

Taylor J, Molinaro A, Butowski N, Prados M Neurooncol Pract. 2019; 4(4):201-208.

PMID: 31385993 PMC: 6655446. DOI: 10.1093/nop/npw034.

Prognostic potential of initial CT changes for progression-free survival in gefitinib-treated patients with advanced adenocarcinoma of the lung: a preliminary analysis.

Wu Y, Hsu H, Chang W, Tung H, Ko K, Hsu Y Eur Radiol. 2015; 25(6):1801-13.

PMID: 25577523 DOI: 10.1007/s00330-014-3579-x.

Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study.

Chamberlain M J Neurooncol. 2015; 122(2):329-38.

PMID: 25563816 DOI: 10.1007/s11060-014-1714-9.

Outcomes for patients with anaplastic astrocytoma treated with chemoradiation, radiation therapy alone or radiation therapy followed by chemotherapy: a retrospective review within the era of temozolomide.

Shonka N, Theeler B, Cahill D, Yung A, Smith L, Lei X J Neurooncol. 2013; 113(2):305-11.

PMID: 23526410 DOI: 10.1007/s11060-013-1116-4.

Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission.

Buyse M, Michiels S, Squifflet P, Lucchesi K, Hellstrand K, Brune M Haematologica. 2011; 96(8):1106-12.

PMID: 21546500 PMC: 3148903. DOI: 10.3324/haematol.2010.039131.

References

Kleihues P, Louis D, Scheithauer B, Rorke L, Reifenberger G, Burger P . The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002; 61(3):215-25; discussion 226-9. DOI: 10.1093/jnen/61.3.215. View

Devineni D, Klein-Szanto A, Gallo J . Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470. Cancer Res. 1996; 56(9):1983-7. View

Chamberlain M, PRADOS M, Silver P, Levin V . A phase II trial of oral melphalan in recurrent primary brain tumors. Am J Clin Oncol. 1988; 11(1):52-4. DOI: 10.1097/00000421-198802000-00011. View

Van Tassel P, Bruner J, Maor M, Leeds N, Gleason M, Yung W . MR of toxic effects of accelerated fractionation radiation therapy and carboplatin chemotherapy for malignant gliomas. AJNR Am J Neuroradiol. 1995; 16(4):715-26. PMC: 8332306. View

WALKER A, Robins M, Weinfeld F . Epidemiology of brain tumors: the national survey of intracranial neoplasms. Neurology. 1985; 35(2):219-26. DOI: 10.1212/wnl.35.2.219. View

Groves M, Puduvalli V, Conrad C, Gilbert M, Yung W, Jaeckle K . Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status. J Neurooncol. 2006; 80(1):83-90. DOI: 10.1007/s11060-006-9160-y. View

Baker S, Wirth M, Statkevich P, Reidenberg P, Alton K, Sartorius S . Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res. 1999; 5(2):309-17. View

Levin V, Shapiro W, Clancy T, OLIVERIO V . The uptake, distribution, and antitumor activity of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea in the murine glioma. Cancer Res. 1970; 30(10):2451-5. View

Decker D, Al Sarraf M, Kresge C, Austin D, Wilner H . Phase II study of aziridinylbenzoquinone (AZQ: NSC-182986) in the treatment of malignant gliomas recurrent after radiation. Preliminary report. J Neurooncol. 1985; 3(1):19-21. DOI: 10.1007/BF00165167. View

10.

Elliott T, Buckner J, Cascino T, Levitt R, OFallon J, Scheithauer B . Phase II study of ifosfamide with mesna in adult patients with recurrent diffuse astrocytoma. J Neurooncol. 1991; 10(1):27-30. DOI: 10.1007/BF00151244. View

11.

Wong E, Hess K, Gleason M, Jaeckle K, Kyritsis A, PRADOS M . Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999; 17(8):2572-8. DOI: 10.1200/JCO.1999.17.8.2572. View

12.

Patel M, McCully C, Godwin K, Balis F . Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. J Neurooncol. 2003; 61(3):203-7. DOI: 10.1023/a:1022592913323. View

13.

Levin V . Pharmacological principles of brain tumor chemotherapy. Adv Neurol. 1976; 15:315-25. View

14.

Murovic J, TUROWSKI K, Wilson C, Hoshino T, Levin V . Computerized tomography in the prognosis of malignant cerebral gliomas. J Neurosurg. 1986; 65(6):799-806. DOI: 10.3171/jns.1986.65.6.0799. View

15.

Levin V, PRADOS M, Yung W, Gleason M, Ictech S, Malec M . Treatment of recurrent gliomas with eflornithine. J Natl Cancer Inst. 1992; 84(18):1432-7. DOI: 10.1093/jnci/84.18.1432. View

16.

Levin V, Edwards M, Wright D, Seager M, Schimberg T, Townsend J . Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep. 1980; 64(2-3):237-44. View

17.

. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol. 2001; 19(2):509-18. DOI: 10.1200/JCO.2001.19.2.509. View

18.

Levin V, Crafts D, Wilson C, Kabra P, HANSCH C, BOLDREY E . Imidazole carboxamides: relationship of lipophilicity to activity against intracerebral murine glioma 26 and preliminary phase II clinical trial of 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) in primary and secondary.... Cancer Chemother Rep. 1975; 59(2 Pt 1):327-31. View

19.

Ren X, Du Q, Huang Y, Ao S, Mei L, Xiong W . Regulation of CDC42 GTPase by proline-rich tyrosine kinase 2 interacting with PSGAP, a novel pleckstrin homology and Src homology 3 domain containing rhoGAP protein. J Cell Biol. 2001; 152(5):971-84. PMC: 2198805. DOI: 10.1083/jcb.152.5.971. View

20.

Sexauer C, Khan A, Burger P, Krischer J, van Eys J, Vats T . Cisplatin in recurrent pediatric brain tumors. A POG Phase II study. A Pediatric Oncology Group Study. Cancer. 1985; 56(7):1497-501. DOI: 10.1002/1097-0142(19851001)56:7<1497::aid-cncr2820560703>3.0.co;2-7. View